Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Receivables - Other (2023 - 2025)

Historic Receivables - Other for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $102030.5.

  • Zhengye Biotechnology Holding's Receivables - Other changed N/A to $102030.5 in Q2 2025 from the same period last year, while for Jun 2025 it was $102030.5, marking a year-over-year change of. This contributed to the annual value of $102707.8 for FY2024, which is 4425.21% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Receivables - Other stood at $102030.5 for Q2 2025.
  • Zhengye Biotechnology Holding's 5-year Receivables - Other high stood at $180831.4 for Q4 2023, and its period low was $102030.5 during Q2 2025.
  • Over the past 3 years, Zhengye Biotechnology Holding's median Receivables - Other value was $102741.2 (recorded in 2024), while the average stood at $128534.4.
  • Examining YoY changes over the last 5 years, Zhengye Biotechnology Holding's Receivables - Other showed a top increase of 4318.4% in 2024 and a maximum decrease of 4318.4% in 2024.
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Receivables - Other stood at $180831.4 in 2023, then plummeted by 43.18% to $102741.2 in 2024, then fell by 0.69% to $102030.5 in 2025.
  • Its last three reported values are $102030.5 in Q2 2025, $102741.2 for Q4 2024, and $180831.4 during Q4 2023.